A drug mix killed glioblastoma cells better in lab tests
Original title: Dactolisib outperforms Rapamycin in potentiating apoptosis induced by XPO1, Bcl-2 and Mcl-1 blockade in preclinical glioblastoma models.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This was only done in lab cells and in tumors grown in eggs, not in people.
The short version
In lab tests, adding one drug helped other drugs kill brain tumor cells.
What was studied. Researchers tested drug mixes on glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary cells grown in the lab. This included tumor stem like cells taken from patients. They compared two drugs, Dactolisib and Rapamycin, each added to the same mix of other drugs. They also grew tumors in a chick egg membrane to test the mix.
What they found. Dactolisib plus the other drugs lowered cell survival and caused more cell death. It worked better than any of the Rapamycin mixes. The difference in cell death was largest in one cell line and in the patient stem like cells. In the egg grown tumors, signs of cell death showed up only when Dactolisib was added.
What this means, and what it doesn't
What it could mean: Tumors can survive treatment by switching to backup survival signals. This work suggests Dactolisib may block one of those backups. For now it is a lead for more lab work, not something a doctor can offer.
What it doesn't mean: This does not mean a new treatment is ready. The work was done in cells in a dish and in tumors grown in eggs, not in people. Nothing here shows the mix is safe or helpful for a person. It is not a cure, and it is not a promise of one. The authors say more lab testing is needed first.
Source: PubMed, October 24, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.